BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Business

  Janssen to Terminate Simeprevir License With Medivir, Effective June 2018

  Medivir will continue to receive royalties on any remaining sales of Olysio/Sovriad (simeprevir) that Janssen will make until that time.

  December 10, 2017

   · 

  1 min read
• Pharm Country

  Incyte Release: Four-Year Phase III Data Analysis Shows Durability of Response of Jakafi (ruxolitinib) in Patients With Polycythemia Vera

  The pre-planned data analysis showed a durable primary response to Jakafi in patients with PV who are resistant to or intolerant of HU and the overall safety profile for Jakafi remained consistent with previously reported 80-week RESPONSE data.

  December 10, 2017

   · 

  12 min read
• Drug Development

  PharmaEssentia Announces Favorable Two-Year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the ASH Annual Meeting 2017

  Results reported last year at ASH 2016 showed that at 12 months, Ropeginterferon alfa-2b demonstrated non-inferiority to hydroxyurea in Complete Hematologic Response.

  December 10, 2017

   · 

  5 min read
• Drug Development

  Blueprint Medicines Announces New Data From Ongoing Phase I Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

  The new data from the dose escalation portion of the Phase I trial showed strong clinical activity regardless of advanced SM subtype, prior treatment with midostaurin or the presence of additional mutations.

  December 10, 2017

   · 

  15 min read
• Genetown

  Takeda and Seattle Genetics to Present Positive Data from Phase III ECHELON-1 Clinical Trial Evaluating ADCETRIS (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

  The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017.

  December 10, 2017

   · 

  29 min read
• Drug Development

  ASH Release: Targeted Therapies Show Promise for Improving Outcomes Across a Spectrum of Hematologic Malignancies

  Four studies being presented today at the 59th ASH Annual Meeting and Exposition in Atlanta highlight the multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.

  December 10, 2017

   · 

  15 min read
• Seattle Genetics Highlights Five-Year Survival Results from Phase I Trial of ADCETRIS (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting

  The presentation highlighted durability data from a phase 1 clinical trial of ADCETRIS in combination with chemotherapy for the treatment of patients with newly diagnosed MTCL, also known as peripheral T-cell lymphoma (PTCL).

  December 10, 2017

   · 

  15 min read
• Genetown

  Syros Announces New Preclinical Data on SY-1365, Its First-in-Class Selective CDK7 Inhibitor, Pointing to a Potential Biomarker of Response and Combination Approach

  Syros today announced that new preclinical data on SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor currently in a Phase 1 clinical trial in advanced solid tumors, show anti-tumor activity in in vitro and in vivo models of blood cancers.

  December 10, 2017

   · 

  6 min read
• Drug Development

  Bioverativ Release: Study Shows Weekly Prophylactic Treatment With ELOCTATE Resulted in Bleed Protection and Target Joint Resolution in People With Hemophilia A

  The analysis is being presented today in a poster session at the 59th Annual Meeting of the American Society of Hematology.

  December 10, 2017

   · 

  10 min read
• Genetown

  Acceleron Announces Updated Results From Ongoing Phase II Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology

  Acceleron announced preliminary results from the ongoing Phase 2 trials with luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

  December 10, 2017

   · 

  9 min read